Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Cut to “Strong Sell” at Zacks Research

Zacks Research cut shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) from a hold rating to a strong sell rating in a report published on Thursday,Zacks.com reports.

Separately, The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday, April 8th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR presently has a consensus rating of “Reduce”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

SGIOY opened at $10.19 on Thursday. The company has a market capitalization of $17.34 billion, a PE ratio of 13.41, a price-to-earnings-growth ratio of 0.76 and a beta of 0.19. Shionogi & Co., Ltd. Unsponsored ADR has a 1 year low of $7.38 and a 1 year high of $12.00. The business has a fifty day simple moving average of $11.03 and a 200 day simple moving average of $9.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.84 and a quick ratio of 5.21.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its quarterly earnings results on Friday, January 30th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.09. The company had revenue of $966.53 million during the quarter, compared to the consensus estimate of $848.42 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.70% and a net margin of 41.82%. Research analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.